Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome

Drug and Alcohol Dependence

Volumn 138, Issue 1, 2014, Pages 109-117

  Leventhal, Adam M ^a,b   Lee, Wonho ^a   Bergen, Andrew W ^c   Swan, Gary E ^c   Tyndale, Rachel F ^d   Lerman, Caryn ^e   Conti, David V ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c SRI INTERNATIONAL   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Dopamine; Genetics; Nicotine dependence; Smoking cessation

Indexed keywords

CARBON MONOXIDE; DOPAMINE BETA MONOOXYGENASE; NICOTINE; NICOTINE PATCH; NICOTINIC RECEPTOR;

ADULT; AEROSOL; ARTICLE; BREATH ANALYSIS; CHROMOSOME 15; CONTROLLED STUDY; DBH GENE; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC RISK; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; TOBACCO DEPENDENCE; TRANSDERMAL PATCH; TREATMENT RESPONSE; GENETICS; HAPLOTYPE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; DOPAMINE BETA-HYDROXYLASE; FEMALE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, NICOTINIC; SEVERITY OF ILLNESS INDEX; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 84897526791     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.02.016     Document Type: Article

References (66)

1. Amos C.I., Gorlov I.P., Dong Q., Wu X., Zhang H., Lu E.Y., Scheet P., Greisinger A.J., Mills G.B., Spitz M.R. Nicotinic acetylcholine receptor region on chromosome 15q25 and lung cancer risk among African Americans: a case-control study. J. Natl. Cancer Inst. 2010, 102:1199-1205.
2. Ashley-Koch A.E., Epstein J.N., Tonev S., FitzGerald3 D., Kane E.M., Anastopoulos A.D., Lachiewicz A.M., Kail K.E., Exelbierd L., Cuccaro M.L., Gilbert J.R., Kollins S.H. Genetic associations with response variability on the continuous performance task in AD/HD families. Annual Meeting for the American Society of Human Genetics 2006.
3. Baker T.B., Piper M.E., McCarthy D.E., Bolt D.M., Smith S.S., Kim S.Y., Colby S., Conti D., Giovino G.A., Hatsukami D., Hyland A., Krishnan-Sarin S., Niaura R., Perkins K.A., Toll B.A. Time to first cigarette in the morning as an index of ability to quit smoking: implications for nicotine dependence. Nicotine Tob. Res. 2007, 9(Suppl. 4):S555-S570.
4. Bergen A.W., Conti D.V., Van Den Berg D., Lee W., Liu J., Li D., Guo N., Mi H., Thomas P.D., Lessov-Schlaggar C.N., Krasnow R., He Y., Nishita D., Jiang R., McClure J.B., Tildesley E., Hops H., Tyndale R.F., Benowitz N.L., Lerman C., Swan G.E. Dopamine genes and nicotine dependence in treatment-seeking and community smokers. Neuropsychopharmacology 2009, 34:2252-2264.
5. Bergen A.W., Javitz H.S., Krasnow R., Nishita D., Michel M., Conti D.V., Liu J., Lee W., Edlund C.K., Hall S., Kwok P.Y., Benowitz N.L., Baker T.B., Tyndale R.F., Lerman C., Swan G.E. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet. Genomics 2013, 23:94-103.
6. Bergen A.W., Javitz H.S., Su L., He Y., Conti D.V., Benowitz N.L., Tyndale R.F., Lerman C., Swan G.E. The DRD4 exon III VNTR, bupropion, and associations with prospective abstinence. Nicotine Tob. Res. 2013, 15:1190-1200.
7. Bhaduri N., Sarkar K., Sinha S., Chattopadhyay A., Mukhopadhyay K. Study on DBH genetic polymorphisms and plasma activity in attention deficit hyperactivity disorder patients from Eastern India. Cell. Mol. Neurobiol. 2010, 30:265-274.
8. Bolt D.M., Piper M.E., McCarthy D.E., Japuntich S.J., Fiore M.C., Smith S.S., Baker T.B. The Wisconsin predicting patients' relapse questionnaire. Nicotine Tob. Res. 2009, 11:481-492.
9. Breslau N., Johnson E.O. Predicting smoking cessation and major depression in nicotine-dependent smokers. Am. J. Public Health 2000, 90:1122-1127.
10. Brewer J.A., Potenza M.N. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem. Pharmacol. 2008, 75:63-75.
11. Bruijnzeel A.W. Tobacco addiction and the dysregulation of brain stress systems. Neurosci. Biobehav. Rev. 2012, 36:1418-1441.
12. Cardenas-Navia L.I., Cruz P., Lin J.C., Rosenberg S.A., Samuels Y. Novel somatic mutations in heterotrimeric G proteins in melanoma. Cancer Biol. Ther. 2010, 10:33-37.
13. Chen L.S., Baker T.B., Piper M.E., Breslau N., Cannon D.S., Doheny K.F., Gogarten S.M., Johnson E.O., Saccone N.L., Wang J.C., Weiss R.B., Goate A.M., Bierut L.J. Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. Am. J. Psychiatry 2012, 169:735-742.
14. Conneely K.N., Boehnke M. So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests. Am. J. Hum. Genet. 2007, 81:1158-1168.
15. Conti D.V., Lee W., Li D., Liu J., Van Den Berg D., Thomas P.D., Bergen A.W., Swan G.E., Tyndale R.F., Benowitz N.L., Lerman C. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum. Mol. Genet. 2008, 17:2834-2848.
16. Cubells J.F., Zabetian C.P. Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology. Psychopharmacology 2004, 174:463-476.
17. D'Souza M.S., Markou A. Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments. Addict. Sci. Clin. Pract. 2011, 6:4-16.
18. David S.P., Brown R.A., Papandonatos G.D., Kahler C.W., Lloyd-Richardson E.E., Munafo M.R., Shields P.G., Lerman C., Strong D., McCaffery J., Niaura R. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob. Res. 2007, 9:821-833.
19. David S.P., Munafo M.R., Murphy M.F., Proctor M., Walton R.T., Johnstone E.C. Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics J. 2008, 8:122-128.
20. David S.P., Strong D.R., Munafo M.R., Brown R.A., Lloyd-Richardson E.E., Wileyto P.E., Evins E.A., Shields P.G., Lerman C., Niaura R. Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob. Res. 2007, 9:1251-1257.
21. De Ruyck K., Nackaerts K., Beels L., Werbrouck J., De Volder A., Meysman M., Salhi B., Van Meerbeeck J., Thierens H. Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. Pharmacogenomics 2010, 11:1053-1063.
22. Excoffier L., Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol. Biol. Evol. 1995, 12:921-927.
23. Fagerstrom K., Russ C., Yu C.R., Yunis C., Foulds J. The Fagerstrom Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data. Nicotine Tob. Res. 2012, 14:1467-1473.
24. Falcone M., Jepson C., Benowitz N., Bergen A.W., Pinto A., Wileyto E.P., Baldwin D., Tyndale R.F., Lerman C., Ray R. Association of the nicotine metabolite ratio and CHRNA5/CHRNA3 polymorphisms with smoking rate among treatment-seeking smokers. Nicotine Tob. Res. 2011, 13:498-503.
25. Faraone S.V., Perlis R.H., Doyle A.E., Smoller J.W., Goralnick J.J., Holmgren M.A., Sklar P. Molecular genetics of attention-deficit/hyperactivity disorder. Biol. Psychiatr. 2005, 57:1313-1323.
26. Greenwood P.M., Sundararajan R., Lin M.K., Kumar R., Fryxell K.J., Parasuraman R. Both a nicotinic single nucleotide polymorphism (SNP) and a noradrenergic SNP modulate working memory performance when attention is manipulated. J. Cogn. Neurosci. 2009, 21:2139-2153.
27. Hartz S.M., Short S.E., Saccone N.L., Culverhouse R., Chen L., Schwantes-An T.H., Coon H., Han Y., Stephens S.H., Sun J., Chen X., Ducci F., et al. Increased genetic vulnerability to smoking at CHRNA5 in early-onset smokers. Arch. Gen. Psychiatry 2012, 69:854-860.
28. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerström K.-O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br. J. Addict. 1991, 86:1119-1127.
29. John U., Meyer C., Rumpf H.J., Hapke U. Probabilities of alcohol high-risk drinking, abuse or dependence estimated on grounds of tobacco smoking and nicotine dependence. Addiction 2003, 98:805-814.
30. Johnson A.D., Handsaker R.E., Pulit S.L., Nizzari M.M., O'Donnell C.J., de Bakker P.I. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008, 24:2938-2939.
31. Kebir O., Tabbane K., Sengupta S., Joober R. Candidate genes and neuropsychological phenotypes in children with ADHD: review of association studies. J. Psychiatr. Neurosci. 2009, 34:88-101.
32. King D.P., Paciga S., Pickering E., Benowitz N.L., Bierut L.J., Conti D.V., Kaprio J., Lerman C., Park P.W. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology 2012, 37:641-650.
33. Lee A.M., Jepson C., Hoffmann E., Epstein L., Hawk L.W., Lerman C., Tyndale R.F. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol. Psychiatr. 2007, 62:635-641.
34. Lerman C., Jepson C., Wileyto E.P., Epstein L.H., Rukstalis M., Patterson F., Kaufmann V., Restine S., Hawk L., Niaura R., Berrettini W. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 2006, 31:231-242.
35. Lerman C., Kaufmann V., Rukstalis M., Patterson F., Perkins K., Audrain-McGovern J., Benowitz N. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann. Intern. Med. 2004, 140:426-433.
36. Lerman C., Roth D., Kaufmann V., Audrain J., Hawk L., Liu A., Niaura R., Epstein L. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend. 2002, 67:219-223.
37. Lerman C., Shields P.G., Wileyto E.P., Audrain J., Hawk L.H., Pinto A., Kucharski S., Krishnan S., Niaura R., Epstein L.H. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol. 2003, 22:541-548.
38. Lerman C., Tyndale R., Patterson F., Wileyto E.P., Shields P.G., Pinto A., Benowitz N. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin. Pharmacol. Ther. 2006, 79:600-608.
39. Lessov-Schlaggar C.N., Lepore R.L., Kristjansson S.D., Schlaggar B.L., Barnes K.A., Petersen S.E., Madden P.A., Heath A.C., Barch D.M. Functional neuroimaging study in identical twin pairs discordant for regular cigarette smoking. Addict. Biol. 2012, 18:98-108.
40. Leventhal A.M., David S.P., Brightman M., Strong D., McGeary J.E., Brown R.A., Lloyd-Richardson E.E., Munafo M., Uhl G.R., Niaura R. Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. Pharmacogenomics J. 2012, 12:86-92.
41. Malaiyandi V., Goodz S.D., Sellers E.M., Tyndale R.F. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiol. Biomarkers Prev. 2006, 15:1812-1819.
42. Meyer J.S., Quenzer L.Q. Psychopharmacology: Drugs, the Brain and Behavior 2004, Sinauer Associates, Sunderland, MA.
43. Munafo M.R., Johnstone E.C., Aveyard P., Marteau T. Lack of association of OPRM1 genotype and smoking cessation. Nicotine Tob. Res. 2013, 15:739-744.
44. Munafo M.R., Johnstone E.C., Walther D., Uhl G.R., Murphy M.F., Aveyard P. CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine Tob. Res. 2011, 13:982-988.
45. Parasuraman R., Greenwood P.M., Kumar R., Fossella J. Beyond heritability: neurotransmitter genes differentially modulate visuospatial attention and working memory. Psychol. Sci. 2005, 16:200-207.
46. Patkar A.A., Vergare M.J., Thornton C.C., Weinstein S.P., Murray H.W., Leone F.T. Nicotine dependence and treatment outcome among African American cocaine-dependent patients. Nicotine Tob. Res. 2003, 5:411-418.
47. Patterson F., Schnoll R.A., Wileyto E.P., Pinto A., Epstein L.H., Shields P.G., Hawk L.W., Tyndale R.F., Benowitz N., Lerman C. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin. Pharmacol. Ther. 2008, 84:320-325.
48. Piper M.E., Piasecki T.M., Federman E.B., Bolt D.M., Smith S.S., Fiore M.C., Baker T.B. A multiple motives approach to tobacco dependence: the Wisconsin Inventory of Smoking Dependence Motives (WISDM-68). J. Consult. Clin. Psychol. 2004, 72:139-154.
49. Pomerleau C.S., Carton S.M., Lutzke M.L., Flessland K.A., Pomerleau O.F. Reliability of the fagerstrom tolerance questionnaire and the fagerstrom test for nicotine dependence. Addict. Behav. 1994, 19:33-39.
50. Pritchard J.K., Stephens M., Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000, 155:945-959.
51. R Development Core Team R: A Language and Environment for Statistical Computing 2008, R Foundation for Statistical Computing, Vienna Austria.
52. Ray R., Mitra N., Baldwin D., Guo M., Patterson F., Heitjan D.F., Jepson C., Wileyto E.P., Wei J., Payne T., Ma J.Z., Li M.D., Lerman C. Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence. Neuropsychopharmacology 2010, 35:1374-1382.
53. Rose J.E., Behm F.M., Drgon T., Johnson C., Uhl G.R. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Mol. Med. 2010, 16:247-253.
54. Sarginson J.E., Killen J.D., Lazzeroni L.C., Fortmann S.P., Ryan H.S., Schatzberg A.F., Murphy G.M. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011, 156B:275-284.
55. Schaid D.J., Rowland C.M., Tines D.E., Jacobson R.M., Poland G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet. 2002, 70:425-434.
56. Siedlinski M., Cho M.H., Bakke P., Gulsvik A., Lomas D.A., Anderson W., Kong X., Rennard S.I., Beaty T.H., Hokanson J.E., Crapo J.D., Silverman E.K. Genome-wide association study of smoking behaviours in patients with COPD. Thorax 2011, 66:894-902.
57. Srivastava V., Deshpande S.N., Thelma B.K. Dopaminergic pathway gene polymorphisms and genetic susceptibility to schizophrenia among north Indians. Neuropsychobiology 2010, 61:64-70.
58. Strasser A.A., Malaiyandi V., Hoffmann E., Tyndale R.F., Lerman C. An association of CYP2A6 genotype and smoking topography. Nicotine Tob. Res. 2007, 9:511-518.
59. Thorgeirsson T.E., Gudbjartsson D.F., Surakka I., Vink J.M., Amin N., Geller F., Sulem P., Rafnar T., Esko T., Walter S., Gieger C., Rawal R., et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat. Genet. 2010, 42:448-453.
60. Tobacco and Genetics Consortium, 2010. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat. Genet. 42, 441-447.
61. Uhl G.R., Liu Q.R., Drgon T., Johnson C., Walther D., Rose J.E., David S.P., Niaura R., Lerman C. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch. Gen. Psychiatry 2008, 65:683-693.
62. USDHHS, 2008. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. U.S. Public Health Service, Rockville, MD.
63. Wassenaar C.A., Dong Q., Wei Q., Amos C.I., Spitz M.R., Tyndale R.F. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J. Natl. Cancer Inst. 2011, 103:1342-1346.
64. Wilkie T.M., Gilbert D.J., Olsen A.S., Chen X.N., Amatruda T.T., Korenberg J.R., Trask B.J., de Jong P., Reed R.R., Simon M.I., et al. Evolution of the mammalian G protein alpha subunit multigene family. Nat. Genet. 1992, 1:85-91.
65. Yamanaka H., Nakajima M., Fukami T., Sakai H., Nakamura A., Katoh M., Takamiya M., Aoki Y., Yokoi T. CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab. Dispos. 2005, 33:1811-1818.
66. Zabetian C.P., Anderson G.M., Buxbaum S.G., Elston R.C., Ichinose H., Nagatsu T., Kim K.S., Kim C.H., Malison R.T., Gelernter J., Cubells J.F. A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. Am. J. Hum. Genet. 2001, 68:515-522.